Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,503.45
(
-1.56%
)
US TECH 100
23,259.60
(
-1.94%
)
Dow Jones
45,547.79
(
-1.03%
)
Brent Oil
108.65
(
4.04%
)
Bitcoin
69,878.00
(
-0.03%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Democritus_of_Abdera post# 83414

Tuesday, 04/06/2010 6:52:47 PM

Tuesday, April 06, 2010 6:52:47 PM

Post# of 257262
Caveat emptor—Alimera moved closer to an IPO with S-1/A filing today. The company aims to sell 6.9M shares (including the 15% underwriter’s overallotment) at $15-17/sh:

http://sec.gov/Archives/edgar/data/1267602/000095012310032434/g20643a4sv1za.htm

Alimera is PSDV’s partner on the Iluvien program for diabetic macular edema, where the phase-3 clinical data have some warts: #msg-44824336, #msg-44830086.

Democritus_of_Abdera astutely predicted in September (before the phase-3 data were released) that Zebra’s Law would come into play: #msg-41337642.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today